MarketBeat
15 Jul 2026, 08:02 UTC · 2h ago
Celcuity Enters Commercial Stage as FDA Approves REVTORPYK for Advanced Breast Cancer
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
MarketBeat
15 Jul 2026, 08:02 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
The FDA granted full approval for REVTORPYK for the treatment of certain HR-positive, HER2-negative advanced breast cancers without a PIK3CA mutation. — FDA approval is the primary value-inflection point for biotech companies, transitioning Celcuity to a commercial-stage business with a viable product.
+0.80Celcuity estimates a served market opportunity of over $6 billion for the second-line setting, potentially exceeding $10 billion including first-line use. — Provides a quantifiable revenue ceiling and justifies the valuation based on the total addressable market (TAM).
+0.60Celcuity plans to submit a supplemental NDA in Q3 for patients with PIK3CA mutations to potentially cover the full second-line market. — Expanding the label to mutant populations would increase the addressable patient base from 60% to 100% of the second-line market.
+0.50Continue reading
6 related stories
Top 3 movers · tap to explore
In Phase III trials, the triplet regimen showed a 7.3-month improvement in progression-free survival over fulvestrant monotherapy (9.3 months vs 2 months). — Strong clinical efficacy data supports the likelihood of high physician adoption and a 'best-in-class' market position.
+0.40The company expects commercial launch later in Q3, contingent on ensuring sufficient drug supply. — Establishes the immediate timeline for revenue generation, though supply chain risks are noted.
+0.20Which stocks this story touches
The company received FDA approval for REVTORPYK, marking a transformative transition to a commercial-stage business with a significant market opportunity.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Benzinga
16h ago
